Multiple Myeloma | Specialty

The multiple myeloma condition center is a comprehensive resource for clinical news and expert insights on multiple myeloma. Read more at OncLive.

Dr Bishop on 34-Month Data With Anitocabtagene Autoleucel in R/R Myeloma

December 23rd 2024

Michael R. Bishop, MD, discusses 34-month data from the iMMagine-1 trial of anitocabtagene autoleucel in relapsed/refractory myeloma.

Dr Shah on the Effects of IVIG on Teclistamab-Associated Infection Risk in Myeloma

December 20th 2024

Mansi R. Shah, MD, on the effects of IVIG on infections in recipients of teclistamab therapy for multiple myeloma.

The OncFive: Top Oncology Articles for the Week of 12/8

December 14th 2024

Fixed-duration acalabrutinib combination improves PFS in CLL, imlunestrant ± abemaciclib boosts PFS in ESR1-mutated ER+ breast cancer, and more.

Cilta-Cel Leads to 100% MRD-Negativity Rate in High-Risk Smoldering Multiple Myeloma

December 11th 2024

Cilta-cel without induction therapy in high-risk smoldering myeloma marked the first study of CAR T-cell therapy in a precursor cancer setting.

Anitocabtagene Autoleucel Elicits Deep Responses in Relapsed/Refractory Multiple Myeloma

December 11th 2024

Anito-cel elicited an ORR of 97% with acceptable safety in patients with relapsed or refractory multiple myeloma.

Isa-RVd Induction Provides Significant PFS Benefit in Newly Diagnosed Multiple Myeloma

December 10th 2024

Isa-RVd given as induction treatment without consolidation led to a 30% reduction in the risk of disease progression or death vs RVd in multiple myeloma.

Lisaftoclax Plus Pd Yields High ORRs and Shows Encouraging Safety Profile in RRMM

December 10th 2024

The BCL-2 inhibitor lisaftoclax was well tolerated and produced encouraging responses in relapsed/refractory multiple myeloma when given in combination with Pd.

Ide-Cel Shows Real-World Efficacy in CNS Multiple Myeloma

December 10th 2024

Real-world data showed ide-cel was active in patients with central nervous system manifestations of multiple myeloma.

Arlo-cel Elicits 87% ORR in Heavily Pretreated, Relapsed/Refractory Multiple Myeloma

December 10th 2024

The GPRC5D-targeting CAR T-cell therapy arlocabtagene autoleucel also yielded a 53% complete response rate in relapsed/refractory multiple myeloma.

Cilta-Cel Improves MRD-Negativity Rates in Lenalidomide-Refractory Myeloma

December 10th 2024

Cilta-cel boosted MRD-negativity rates in lenalidomide-refractory multiple myeloma, according to updated results from CARTITUDE-4.

Breaking the News in Myeloma, GVHD, and NHL, With Drs Rajkumar, Farhadfar, and Smith

December 10th 2024

S. Vincent Rajkumar, MD, of Mayo Clinic; Nosha Farhadfar, MD, of Methodist Physician Practices; and Sonali Smith, MD, of University of Chicago Medicine, sit down with Chandler Park, MD, FACP, to discuss the latest in multiple myeloma, graft-vs-host disease, and non-Hodgkin lymphoma, respectively, from the 2024 ASH Annual Meeting.

Dr Landgren on the Utility of Tocilizumab Prophylaxis in Relapsed/Refractory Multiple Myeloma

December 10th 2024

C. Ola Landgren, MD, PhD, discusses tocilizumab prophylaxis in relapsed/refractory myeloma treated with teclistamab, elranatamab, or talquetamab.

Isatuximab/VRd Elicits Sustained MRD Rates in Newly Diagnosed Myeloma

December 9th 2024

Isatuximab plus initial VRd and Rd maintenance demonstrated deep responses and MRD negativity in transplant-ineligible newly diagnosed multiple myeloma.

Belantamab Mafodotin Combo Could Be New SOC for Relapsed/Refractory Multiple Myeloma

December 9th 2024

Belantamab mafodotin plus bortezomib/dexamethasone improved OS over daratumumab plus bortezomib/dexamethasone in relapsed/refractory multiple myeloma.

Dr Rifkin on Efficacy and Safety Data From the Dreamm-7 Trial in R/R Myeloma

December 9th 2024

Robert M. Rifkin, MD, FACP, discusses the safety and efficacy of the phase 3 Dreamm-7 trial in patients with relapsed/refractory multiple myeloma.

Maintenance Teclistamab With or Without Lenalidomide Is Safe, Active in Newly Diagnosed Myeloma

December 9th 2024

Maintenance therapy with teclistamab with or without lenalidomide was safe and efficacious in newly diagnosed multiple myeloma.

Dr Siegel on the Preliminary Use of Mezigdomide in Relapsed/Refractory Myeloma

December 9th 2024

David Samuel Dicapua Siegel, MD, discusses preliminary findings from the phase 1/2 CA057-003 trial of mezigdomide in relapsed/refractory multiple myeloma.

Daratumumab Significantly Improves PFS, Extends OS in Smoldering Myeloma

December 8th 2024

Subcutaneous daratumumab reduced the risk for disease progression or death vs active monitoring in intermediate- or high-risk smoldering multiple myeloma.

Dr Kaddoura on Genomic Determinants of Outcomes in IGH/CCND1+ Myeloma Treated With Venetoclax

December 8th 2024

Marcella Ali Kaddoura, MD, discusses genomic determinants of clinical outcomes in myeloma with t(11;14)(CCND1;IGH) treated with venetoclax.

D-VRd Deepens MRD Responses in Transplant-Ineligible or -Deferred Newly Diagnosed Myeloma

December 8th 2024

Daratumumab plus VRd improved MRD responses and progression-free survival in transplant-ineligible or -deferred newly diagnosed multiple myeloma.